TNF Pharmaceuticals Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule
TNF Pharmaceuticals Inc. has regained compliance with Nasdaq's minimum bid price requirement, confirmed on September 16, 2025. The company maintained a minimum bid price of $1.00 for 10 consecutive business days, meeting Nasdaq Listing Rule 5550 (a)(2). Executive Chairman Joshua Silverman expressed satisfaction with this achievement and emphasized the company's focus on growth and enhancing shareholder value, with further updates expected soon.
TNF Pharmaceuticals Inc. has announced that it has regained compliance with the Nasdaq Stock Market’s minimum bid price requirement. The company received written confirmation from Nasdaq on September 16, 2025, stating that it met the $1.00 minimum bid price requirement as stipulated under Nasdaq Listing Rule 5550 (a)(2). This compliance was achieved after the company’s shares maintained a minimum bid price of $1.00 for 10 consecutive business days. Joshua Silverman, Executive Chairman of TNF Pharmaceuticals, expressed satisfaction with meeting Nasdaq’s listing standards and indicated that the company is focused on building a strong strategic platform for growth and enhancing shareholder value. Further updates for shareholders are expected in the coming weeks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250917806538) on September 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
